Observational studyDiabetologia2014
Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin.
Observational study in Diabetologia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01825148 (Clinical Proof-of-principle of the Determination of the Beta Cell Mass in Vivo by SPECT Imaging With the 111-In-labeled GLP-1 Analogue DTPA), which is not on this map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Proof-of-principle of the Determination of the Beta Cell Mass in Vivo by SPECT Imaging With the 111-In-labeled GLP-1 Analogue DTPA(Diethylenetriamine Pentaacetic Acid)-[K40]-Exendin 4
Who cites it
65 citing papers in PubMed, 140 citations in OpenAlex.
- Cross-sectional and Test-Retest Characterization of PET with [(18)F]FP-(+)-DTBZ for β Cell Mass Estimates in Diabetes.Molecular imaging and biology · 2016Trial
- Quantitative β-Cell Mass Imaging Redefines Disease Staging and Glycemic Control in Type 1 Diabetes.Diabetes · 2026Article
- miRNA-642a-3p protects β cells from glucolipotoxicity.Molecular therapy. Nucleic acids · 2025Article
- Multiorgan Imaging for Interorgan Crosstalk in Cardiometabolic Diseases.Circulation research · 2025Review
- Morphological and functional alterations in type 2 diabetes pancreata assessed with MRI-based metrics and [Frontiers in endocrinology · 2025Article
- Validation of radiolabelled exendin for beta cell imaging by ex vivo autoradiography and immunohistochemistry of human pancreas.EJNMMI research · 2024Article
- New Radiolabeled Exendin Analogues Show Reduced Renal Retention.Molecular pharmaceutics · 2023Article
- Theranostic in GLP-1R molecular imaging: challenges and emerging opportunities.Frontiers in molecular biosciences · 2023Review
- Multivalent γ-PGA-Exendin-4 Conjugates to Target Pancreatic β-Cells.Chembiochem : a European journal of chemical biology · 2022Article
- RNA aptamers specific for transmembrane p24 trafficking protein 6 and Clusterin for the targeted delivery of imaging reagents and RNA therapeutics to human β cells.Nature communications · 2022Article
- Imaging evaluation of the pancreas in diabetic patients.Abdominal radiology (New York) · 2022Review
- Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [Molecules (Basel, Switzerland) · 2022Article
- Noninvasive Evaluation of GIP Effects on β-Cell Mass Under High-Fat Diet.Frontiers in endocrinology · 2022Article
- Restoring normal islet mass and function in type 1 diabetes through regenerative medicine and tissue engineering.The lancet. Diabetes & endocrinology · 2021Review
- The β Cell in Diabetes: Integrating Biomarkers With Functional Measures.Endocrine reviews · 2021Review
- First-in-Human Evaluation of Positron Emission Tomography/Computed Tomography With [Frontiers in endocrinology · 2021Article
- Non-invasive Beta-cell Imaging: Visualization, Quantification, and Beyond.Frontiers in endocrinology · 2021Review
- Association of glucagon-like peptide-1 receptor-targeted imaging probe with in vivo glucagon-like peptide-1 receptor agonist glucose-lowering effects.Journal of diabetes investigation · 2020Article
- Beta Cell Imaging-From Pre-Clinical Validation to First in Man Testing.International journal of molecular sciences · 2020Review
- Current Progress and Perspective: Clinical Imaging of Islet Transplantation.Life (Basel, Switzerland) · 2020Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
17 authors at 8 institutions in 4 countries.
Funding
Abstract
aims/hypothesisA reliable method for in vivo quantification of pancreatic beta cell mass (BCM) could lead to further insight into the pathophysiology of diabetes. The glucagon-like peptide 1 receptor, abundantly expressed on beta cells, may be a suitable target for imaging. We investigated the potential of radiotracer imaging with the GLP-1 analogue exendin labelled with indium-111 for determination of BCM in vivo in a rodent model of beta cell loss and in patients with type 1 diabetes and healthy individuals.
methodsThe targeting of (111)In-labelled exendin was examined in a rat model of alloxan-induced beta cell loss. Rats were injected with 15 MBq (111)In-labelled exendin and single photon emission computed tomography (SPECT) acquisition was performed 1 h post injection, followed by dissection, biodistribution and ex vivo autoradiography studies of pancreatic sections. BCM was determined by morphometric analysis after staining with an anti-insulin antibody. For clinical evaluation SPECT was acquired 4, 24 and 48 h after injection of 150 MBq (111)In-labelled exendin in five patients with type 1 diabetes and five healthy individuals. The tracer uptake was determined by quantitative analysis of the SPECT images.
resultsIn rats, (111)In-labelled exendin specifically targets the beta cells and pancreatic uptake is highly correlated with BCM. In humans, the pancreas was visible in SPECT images and the pancreatic uptake showed high interindividual variation with a substantially lower uptake in patients with type 1 diabetes. CONCLUSIONS/
interpretationThese studies indicate that (111)In-labelled exendin may be suitable for non-invasive quantification of BCM.
trial registrationClinicalTrials.gov NCT01825148, EudraCT: 2012-000619-10.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.